Immunogenic Cell Death, DAMPs and Prothymosin α as a Putative Anticancer Immune Response Biomarker

The new and increasingly studied concept of immunogenic cell death (ICD) revealed a previously unknown perspective of the various regulated cell death (RCD) modalities, elucidating their immunogenic properties and rendering obsolete the notion that immune stimulation is solely the outcome of necrosis. A distinct characteristic of ICD is the release of danger-associated molecular patterns (DAMPs) by dying and/or dead cells. Thus, several members of the DAMP family, such as the well-characterized heat shock proteins (HSPs) HSP70 and HSP90, the high-mobility group box 1 protein and calreticulin, and the thymic polypeptide prothymosin alpha (proT alpha) and its immunoreactive fragment proT alpha(100-109), are being studied as potential diagnostic tools and/or possible therapeutic agents. Here, we present the basic aspects and mechanisms of both ICD and other immunogenic RCD forms; denote the role of DAMPs in ICD; and further exploit the relevance of human proT alpha and proT alpha(100-109) in ICD, highlighting their possible clinical applications. Furthermore, we present the preliminary results of our in vitro studies, which show a direct correlation between the concentration of proT alpha/proT alpha(100-109) and the levels of cancer cell apoptosis, induced by anticancer agents and gamma-radiation.

Automated summary

Studies have shown that immunogenic cell death (ICD) is a widely studied concept, revealing the immunogenic properties of different regulated cell death modalities and emphasizing the importance of danger-associated molecular patterns (DAMPs) released by dying or dead cells. Experimental results suggest that human proT alpha and its immunoreactive fragment may have potential clinical applications in ICD.